US Stock Movement｜Hims & Hers Health surged over 35% after hours, as Novo Nordisk plans to sell its weight-loss drug on Hims’ platform

Gelonghui, March 7th｜Hims & Hers Health (HIMS.US) surged more than 35% in after-hours US trading. According to reports, Novo Nordisk plans to sell its weight-loss drugs on the Hims & Hers Health Inc. platform, thereby ending a highly publicized dispute between the two companies that escalated into legal action last month. A source familiar with the matter, who requested anonymity, said Novo Nordisk and Hims could announce the establishment of a new partnership as early as next Monday. The two companies had reached a similar agreement last year, but Novo Nordisk unilaterally terminated the deal after Hims refused to stop marketing and selling generic versions of the drug.